Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Dec 8, 2022--

Related Keywords

Germany ,Illinois ,United States ,Bad Homburg ,Hessen ,Lake Zurich ,Joanie Clougherty ,John Ducker ,Acrotech Biopharma ,Fresenius Kabi Pralatrexate ,Fresenius Kabi ,Linkedin ,Fresenius Kabi United States ,Pralatrexate Injection ,Kabi Pralatrexate Injection ,Kabi Pralatrexate ,Business Wire ,Fresenius Kabi United ,Avoid Pralatrexate ,Important Safety Information ,